Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H1 2017

  • ID: 4311870
  • Drug Pipelines
  • 73 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Asana BioSciences LLC
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Onconova Therapeutics Inc
  • Oribase Pharma
  • MORE
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H1 2017

Summary:

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1.

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 5 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Respiratory, Central Nervous System, Immunology, Musculoskeletal Disorders and Ophthalmology which include indications Solid Tumor, Lymphangioleiomyomatosis, Non-Small Cell Lung Cancer, Ulcerative Colitis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alcohol Addiction, Alzheimer's Disease, Bladder Cancer, Breast Cancer, Cancer Pain, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Keratoconjunctivitis sicca (Dry Eye), Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Systemic Sclerosis (Scleroderma) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2017, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
  • The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Asana BioSciences LLC
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Onconova Therapeutics Inc
  • Oribase Pharma
  • MORE
  1. Introduction
  2. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
  3. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  14. AbbVie Inc
  15. Asana BioSciences LLC
  16. AstraZeneca Plc
  17. Boehringer Ingelheim GmbH
  18. Onconova Therapeutics Inc
  19. Oribase Pharma
  20. TopiVert Ltd
  21. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
  22. AD-80 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. ASN-006 - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. ilorasertib - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. JRP-890 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. nintedanib - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. ON-150030 - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. OR-0512 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. saracatinib difumarate - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. TOP-1210 - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. TOP-1288 - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. TOP-1630 - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. TPX-0005 - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
  71. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
  72. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
  73. Featured News & Press Releases
  74. Jun 05, 2017: Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO
  75. May 24, 2017: IPF patients treated with OFEV (nintedanib) versus placebo were twice as likely to have improved or stable lung function
  76. Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data on ON dual FLT3 and Src inhibitor 150030 at 2017 American Association of Cancer Research Annual Meeting
  77. Mar 20, 2017: Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases
  78. Dec 14, 2016: Nintedanib granted orphan drug designation for treatment of mesothelioma
  79. Dec 07, 2016: Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer
  80. Nov 28, 2016: TopiVert Receives IND Approval for TOP1630 in the Treatment of Dry Eye Syndrome
  81. Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
  82. Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO
  83. Oct 06, 2016: First Patients Dosed in Phase 2a Proof-of-Concept Study With Rectal Formulation of TopiVert TOP1288 in Moderate to Severe Ulcerative Colitis
  84. Sep 09, 2016: Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
  85. Sep 07, 2016: New long-term data demonstrates continued safety and beneficial effect of OFEV (nintedanib) for patients with IPF
  86. Jul 27, 2016: First Study Initiated to Evaluate the Effect of Ofev Treatment on Biomarkers that may Predict IPF Progression
  87. Jun 30, 2016: INMARK now enrolling: first study to evaluate the effect of OFEV (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients
  88. Jun 27, 2016: New analysis of INPULSIS trials demonstrates efficacy of OFEV (nintedanib) across a range of IPF patients using broader diagnostic criteria
  89. Appendix
  90. Methodology
  91. Coverage
  92. Secondary Research
  93. Primary Research
  94. Expert Panel Validation
  95. Contact Us
  96. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Companies, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Number of Products under Investigation by Universities/Institutes, H1
  11. Products under Investigation by Universities/Institutes, H1
  12. Number of Products by Stage and Mechanism of Actions, H1
  13. Number of Products by Stage and Route of Administration, H1
  14. Number of Products by Stage and Molecule Type, H1
  15. Pipeline by AbbVie Inc, H1
  16. Pipeline by Asana BioSciences LLC, H1
  17. Pipeline by AstraZeneca Plc, H1
  18. Pipeline by Boehringer Ingelheim GmbH, H1
  19. Pipeline by Onconova Therapeutics Inc, H1
  20. Pipeline by Oribase Pharma, H1
  21. Pipeline by TopiVert Ltd, H1
  22. Dormant Products, H1
  23. Dormant Products, H1 2017 (Contd..1), H1
  24. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Asana BioSciences LLC
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Onconova Therapeutics Inc
  • Oribase Pharma
  • TopiVert Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll